The cure for Type-1 diabetes may only be days away claim scientists in Melbourne.
Eliminating the need
Panama City, Panama
The cure for Type-1 diabetes may only be days away claim scientists in Melbourne.
Eliminating the need
Restoring memory after brain damage may be accomplished with the use of neural stem cells.
The length and quality of life for individuals with specific forms of muscular dystrophy is greatly affected by heart disease, which is also the leading cause of death in the United States.
“Embryonic stem cell research did not save me; cord blood research did. I am living proof that there are promising and useful alternatives to embryonic stem cell research and that embryos do not need to be killed to achieve medical breakthroughs.”
—Nathan Salley, of Arvada, Colo., before a congressional subcommittee
Statements such as the one above have been publicly absent while legislatures across the country and Congress continue to debate the question of stem cell research.
The question is why has this been the case.
“A miracle” is what Eve Cottier calls it.
A cancerous brain tumor which was inoperable, was deciding life for her husband Jim. But a year after his diagnosis, he says is gone.
An MRI on Oct. 16 showed no tumor after he underwent aggressive chemotherapy and a stem cell transplant. Radiation was used when the tumor recurred, and all signs point to it being wiped out.
Even the tumor’s root in the top of Jim’s brain stem in the middle of his head is gone.
“I’m thrilled, thrilled, thrilled, thrilled,” Eve Cottier said Wednesday morning at Angelo’s Pizza, the Ironwood restaurant they opened in 1980 with Jim’s father, Dick Cottier.
To celebrate the Cottiers’ good news, a regular coffee group enjoyed an apple pie baked by Dennis Beals’ wife, Susan, at mid-morning.
“I’m ecstatic, grateful,” Eve continued. “It’s a miracle.”
The prayers from the community, Jim’s positive attitude, and the miracle of medical science all played a role in Jim’s recovery says Eve.
When Jim went to Grand View Hospital suffering from weakness and coordination problems, the walnut-sized brain tumor was discovered Oct. 9, 2006.
He was given a diagnosis of anaplastic large cell lymphoma type t cell — cancer — after a needle biopsy was performed later that month.
At St. Mary’s Clinic Duluth, doctors tried to shrink the tumor by giving Jim six courses of chemotherapy over 90 days.
To get a stem cell transplant, the Cottiers went to the Mayo Clinic in Rochester, Minnesota in early February of this year.
Jim’s stem cells were frozen after being removed from his blood. His cancer was then killed off by administering an extremely high dose of chemotherapy.
“That was tough,” Eve Cottier said.
He couldn’t eat without vomiting. He was incredibly weak.
His stem cells began the work of rebuilding his immune system when they were transfused back into his body on February 22nd.
Mid-March marked his return home.
“All was well,” Eve Cottier said, when the family went back to Mayo for the 100-day checkup in May 29th.
They thought it was going to be over, but their happiness was short lived.
“Two weeks later, he started slipping very badly,” she said.
“The tumor came back with a vengeance,” Eve Cottier said, referring to an MRI performed in Duluth in June 21st.
It only took 3 weeks for the tumor to become four to five times bigger.
Jim Cottier began a 25-day course of radiation at Duluth.
The cost of fuel and travel distance made a daily commute impractical despite the fact the treatment only took minutes.
They drove home to Ironwood on Friday after the last treatment of the week following a Monday through Thursday stay at a downtown Best Western near the hospital.
July 26th marked the final radiation treatment, and subsequent MRI performed less than 30 days later showed a thumbnail sized tumor remaining despite the tumors shrinking.
“The oncologist told us to go home and enjoy whatever time we had left,” Eve Cottier said.
The radiation and the stem cell transplant had not worked according to the doctor.
However, the radiologist still kept his fingers crossed.
Even after the last treatment, radiation remains effective for six to eight weeks stated the radiologist.
After another MRI was performed in October 18th, the results revealed that the tumor had disappeared.
“It is gone. The root is gone,” Jim Cottier said.
“To me, it’s a miracle. I think it’s all the prayers,” Eve Cottier said.
A raffle benefit and silent auction was held, as well as a spaghetti dinner was held in late January before the family took another trip to Mayo.
Prayers continued to come Jim’s way from the local community.
“We are extremely grateful to the community for their support,” Eve Cottier said. “We think that all of their prayers have given us a miracle.”
She says her husband is a fighter.
“Attitude is a big thing. If you let it beat you, you will be beat,” she said.
Jim Cottier understates the obvious, “it was not a pleasant year,” as he slowly regains his strength.
He says he appreciates the days he gets up feeling good. There are about as many good days as bad days now.
And even the bad days are better than they used to be.
“I appreciate that I’m going to go on,” he said.
Eye surgeon Virendar Sangwan has perfected a procedure so cutting-edge that most who have tried it have failed. Dr. Sangwan’s colleague, Geeta Vemuganti, grows corneas in a petri dish from stem cells. Dr. Sangwan then surgically implants these corneas into patients
Sufferers of a rare and debilitating skin disease may be aided by a combination of gene therapy and stem cells according to scientists and doctors in Italy. The same team also showed how stem cells can repair damaged eyes.
To generate new organs or tissues, stem cells, which are essentially
Highlighting the increasing therapeutic use of autologous (one’s own) cord blood stem cells for transplant and regenerative medicine, including treatments for neurological repair, juvenile diabetes, and blood and immune disorders, two separate data abstracts were displayed today at the annual scientific meeting of the AABB. The advancement of these treatments was part of the focus as well, and the important role of family (or private) cord blood banks was demonstrated. The international association of medical professionals and institutions focused on transfusion, transplantation and cellular therapy.
In order to treat aplastic anemia, an individual’s own cord blood stem cells were released in the first study which analyzed four cases. The transplants were conducted at three different institutions: Children’s Hospital in Seattle, City of Hope (Los Angeles), and the University of Minnesota. Cord Blood Registry was responsible for processing and storing the cord blood prior to treatment.
The cases demonstrate that this approach is amenable to use at different treatment centers across the United States and also suggests that autologous cord blood transplantation for aplastic anemia is a safe and effective treatment protocol.
“Aplastic anemia is a life-threatening disease with no known cause that can be acquired at any time in life and is difficult to treat,” said lead study investigator Dr. David T. Harris, Ph.D., professor of immunology at the University of Arizona and scientific director of Cord Blood Registry. “This study offers evidence that transplant physicians have a safe and effective weapon for combating this disease for patients who have access to their own cord blood stem cells.”
The analysis also showed that:
— The average time to engraftment (the point at which the stem cells start to generate new blood cells) for cord blood is between 21 and 35 days according to the National Marrow Donor Program (NMDP). Engraftment averaged 22 days across the four cases and in one patient, occurred as early as two day after transplantation.
— Marking the longest period of time a family-banked cord blood sample has been stored prior to use, one of the autologous samples used was stored for 9.5 years.
Use in both regenerative and traditional medicine applications was documented in a second report involving 13 cases of autologous cord blood stem cell use. An increase in samples requested for regenerative medicine applications was indicated by the data and a rising demand for autologous cord blood over the last 10 years was also suggested.
The report documented nine samples released for regenerative therapies in addition to the four cases of aplastic anemia (reviewed in detail in the first study).
— Stem cell infusions were conducted at Duke University and Children’s Memorial Hospital in Chicago. Six samples were released to treat neurological conditions, including traumatic brain injury (one sample), anoxic brain injury (one sample), and cerebral palsy (four samples). Some anecdotal reports of improvement in quality of life, and anecdotal evidence by physicians involved with these cases suggests that the treatments were safe. This was because these six samples were not released as part of any specific clinical trial. Two more samples were released for treatment of cerebral palsy since the study period ended.
— As part of an ongoing clinical trial at the University of Florida, two client samples were released for type 1 diabetes. Possibly slowing the destruction of their insulin-producing cells and resetting the immune system, preliminary data from the first seven patients in the trial show the stem cell infusion appears to have reduced their disease severity.
— To treat a diagnosis of a rare immune disorder, one additional sample was released for an experimental autologous stem cell infusion.
“Cord blood stem cells are increasingly being used by transplant physicians in regenerative medicine because of their demonstrated ability to produce almost all of the cell types of the body,” said Harris. “These cases provide physicians and researchers with additional insight into how cord blood stem cells may be used to treat more conditions and ultimately benefit more patients.”
Regenerative medicine therapies could provide benefits to approximately one in three Americans according to current estimates. Currently, the U.S. alone is conducting more than 200 National Institutes of Health (NIH) funded clinical trials with cord blood.
Existing as the most recommended cord blood bank by obstetricians for eventual familial use in transplantation and regenerative medicine, Cord Blood Registry(R) (CBR(R)) is the largest cord blood stem cell processing and cryopreservation service. For more than 190,000 newborns throughout the world, Cord Blood Registry preserves cord blood stem cells. Amounting to a number eclipsing any other family cord blood bank, the AABB accredited CBR has released more than 55 client cord blood units for specific therapeutic use. Focusing on the collection, processing and storage technologies to optimize quality and cell yield, the company
One year after receiving adult stem cell treatment in Bangkok, Thailand, William Bernhardt says his life has been changed.
The Desoto, Missouri, native said; “my chest doesn’t hurt anymore, my arm doesn
Patients with previously hard-to-heal breaks in the long bones of their thighs, shins or arms, achieved repair in 91 percent of fracture cases due to stem cell therapy stated Aastrom Biosciences Inc.
33 patients with severe bone breaks that had previously failed to join from standard treatments had stem cells surgically inserted at their fracture sites in a study using stem cells developed by Aastrom. Today at a medical meeting in Boston, the Ann Arbor, Michigan-based company reported that the fractures of 30 patients had healed a year following stem cell therapy.
“We are treating patients that have not healed in the past and are unlikely to heal in the future with normal procedures,” said Elmar Burchardt, the company’s vice president of medical affairs, in a telephone interview. “It’s a completely new approach for bone treatment and tissue regeneration with the idea of restoring its original architecture.”
Aastrom has created a technique for expanding and purifying patients’ own stem cells as a therapy, and is one of several U.S. companies working to bring stem cell-based treatments to market.
Establishing efficacy in a disease that restricts blood circulation in limbs is also part of company tests in addition to testing its approach in several orthopedic uses. Spinal cord injuries and heart disease treatment development is also in the works.
Due to a poor blood supply, osteonecrosis is a condition that damages bone in the hips and other areas. The company is furthest along in testing its cells to treat this rare condition. The company has entered the final stage towards regulatory approval. They have recruited 120 osteonecrosis patients for a last phase study. Burchardt said that as soon as 2010, clearance from the U.S. Food and drug Administration could be sought.
The 30 bone-fracture patients who were deemed by the company to have healed all had bone scans that showed “multiple contact points” between pieces of bone that were formerly fragmented, Burchardt said. The patients’ limbs now “are fully weight-bearing and have full range of motion,” he said.
Copyright © 2025 · Generate Child Theme on Genesis Framework · WordPress · Log in